Chemoprevention of lung cancer: concepts and strategies

References

• Jemal A, Tiwari RC, Murray T et al. Cancer statistics, 2005. CA Cancer J. Clin. 55, 10–30 (2005).
   PubMed Web of Science ®Google Scholar
• Chute JP, Chen T, Feigal E et al. Twenty years of Phase III trials for patients with extensive-stage small cell lung cancer: perceptible progress. J. Clin. Oncol. 17, 1794–1801 (1999).
   PubMed Web of Science ®Google Scholar
• Simon GR, Wagner H. Small cell lung cancer. Chest 123, S259–S271 (2003).
   PubMed Web of Science ®Google Scholar
• Albain KS, Crowley JJ, LeBlanc M et al. Survival determinants in extensive-stage non-small cell lung cancer: the Southwest Oncology Group experience. J. Clin. Oncol. 9, 1618–1626 (1991).
   PubMed Web of Science ®Google Scholar
• Sandler AB. Chemotherapy for small cell lung cancer. Semin. Oncol. 30, 9–25 (2003).
   PubMed Web of Science ®Google Scholar
• Sekido Y, Fong K, Minna J. Cancer of the luna. In: Cancer: Principles and Practice of Oncology, Sixth Edition. DeVita VT Jr, Hellman S, Rosenberg SA (Eds), Lippincott-Raven, PA, USA, 917–1018 (2001).
   Google Scholar
• Mountain C. Revisions in the international system for staging lung cancer. Chest 17, 1–60 (1997).
   Google Scholar
• Dillman RO, Hemdon J, Seagren SL et al. Improved survival in Stage III non-small-cell lung cancer: seven-year follow-up of Cancer and Leukemia Group B (CALGB) 8433 trial. J. Natl Cancer Inst. 88, 1210–1215 (1996).
   PubMed Web of Science ®Google Scholar
• Sause W, Kolesar P, Taylor S IV et al. Final results of Phase III trial in regionally advanced unresectable non-small cell lung cancer. Radiation Therapy Oncology Group, Eastern Co-operative Oncology Group, and Southwest Oncology Group. Chest 117, 358–364 (2000).
   PubMed Web of Science ®Google Scholar
• Curran WJ Jr, Scott C, Langer C et al. Phase III comparison of sequential vs. concurrant chemoradiation for patients with unresected Stage III non-small cell lung cancer: initial report of Radiation Therapy Oncology Group (RTOG) 9410. Proc. Am. Soc. Clin. Oncol. 19, 484a (2000).
   Google Scholar
• Furuse K, Kubota K, Kawahara M et al. Phase II study of concurrent radiotherapy and chemotherapy for unresectable Stage III non-small-cell lung cancer. Southern Osaka Lung Cancer Study Group. J. Clin. Oncol. 13, 869–875 (1995).
   PubMed Web of Science ®Google Scholar
• Furuse K, Fukuoka M, Kawahara M et al. Phase III study of concurrent versus sequential thoracic radiotherapy in combination with mitomycin, vindesine, and cisplatin in unresectable Stage III non-small-cell lung cancer. J. Clin. Oncol. 17, 2692–2699 (1999).
   PubMed Web of Science ®Google Scholar
• Non-Small Cell Lung Cancer CollaborativeGroup. Chemotherapy in non-small cell lung cancer: a meta-analysis using updated data on individual patients from 52 randomised clinical trials. Br. Med. J. 311, 899–909 (1995).
   PubMedGoogle Scholar
• Wingo PA, Reis LA, Giovino GA et al. Annual report to the nation on the status of cancer, 1973–1996, with a special section on lung cancer and tobacco smoking. J. Natl Cancer Inst. 91, 675–690 (1999).
   PubMed Web of Science ®Google Scholar
• Samet JM. Health benefits of smoking cessation. Clin. Chest Med. 12, 669–679 (1991).
   PubMed Web of Science ®Google Scholar
• Samet JM, Wiggins CL, Humble CG et al. Cigarette smoking and lung cancer in New Mexico. Am. Rev. Respir. Dis. 137, 1110–1113 (1988).
   PubMedGoogle Scholar
• Garfinkel L, Stellman SD. Smoking and lung cancer in women: findings in a prospective study. Cancer Res. 48, 6951–6955 (1988).
   PubMed Web of Science ®Google Scholar
• Halpern MT, Gillespie BW, Warner KE. Patterns of absolute risk of lung cancer mortality in former smokers. J. Natl Cancer Inst. 85, 457–464 (1993).
   PubMed Web of Science ®Google Scholar
• Lubin JH, Blot WJ. Lung cancer and smoking cessation: patterns of risk. J. Natl Cancer Inst. 85, 422–423 (1993).
   PubMedGoogle Scholar
• Sobue T, Yamaguchi N, Suzuki T et al. Lung cancer incidence rate for male ex-smokers according to age at cessation of smoking. Jpn J. Cancer Res. 84, 601–607 (1993).
   PubMedGoogle Scholar
• Risch HA, Howe GR, Jain M et al. Are female smokers at higher risk for lung cancer than male smokers? A case-control analysis by histologic subtype. Am. J. Epidemiol. 138, 281–293 (1993).
   PubMed Web of Science ®Google Scholar
• Strauss G, Gleason R, Caro J et al. Screening for lung cancer: another look, a different view. Proc. Sixth World Conf. Lung Cancer 81 (1994).
   Google Scholar
• Tong L, Spitz MR, Fueger JJ et al. Lung carcinoma in former smokers. Cancer 78, 1004–1010 (1996).
   PubMed Web of Science ®Google Scholar
• Bach PB, Kattan MW, Thornquist MD et al. Variations in lung cancer risk among smokers. J. Natl Cancer Inst. 95, 470–478 (2003).
   PubMedGoogle Scholar
• Fisher B, Constantino JP, Wickerham DL et al. Tamoxifen for prevention of breast cancer: report of the National Surgical Adjuvant Breast and Bowel Project P-1 study. J. Natl Cancer Inst. 90, 1371–1388 (1998).
   PubMed Web of Science ®Google Scholar
• Shields PG. Molecular epidemiology of smoking and lung cancer. Oncogene 21, 6870–6876 (2002).
   PubMed Web of Science ®Google Scholar
• Wu X, Zhao H, Suk R et al. Genetic susceptibility to tobacco-related cancer. Oncogene 23, 6500–6523 (2004).
   PubMed Web of Science ®Google Scholar
• Auerbach O, Gere JB, Forman JB et al. Changes in the bronchial epithelium in relation to smoking and cancer of the lung. N. Engl. J. Med. 256, 98–104 (1957).
   Google Scholar
• Auerbach O, Hammond EC, Garfinkel L. Changes in bronchial epithelium in relation to cigarette smoking, 1955–1960 vs. 1970–1977. N. Engl. J. Med. 300, 381–386 (1979).
   PubMed Web of Science ®Google Scholar
• Auerbach O, Stout AP, Hammond EC et al. Changes in bronchial epithelium in relation to cigarette smoking and in relation to lung cancer. N. Engl. J. Med. 265, 253–267 (1961).
   PubMed Web of Science ®Google Scholar
• Slaughter DP, Southwick HW, Smejkal W. Field cancerization in oral stratified squamous epithelium; clinical implications of multicentric origin. Cancer 6, 963–968 (1953).
   PubMed Web of Science ®Google Scholar
• Lippman SM, Hong WK. Molecular markers of the risk of oral cancer. N. Engl. J. Med. 344, 1323–1326 (2001).
   PubMed Web of Science ®Google Scholar
• Sporn MB. Approaches to prevention of epithelial cancer during the preneoplastic period. Cancer Res. 36, 2699–2702 (1976).
   PubMed Web of Science ®Google Scholar
• Sporn MB, Dunlop NM, Newton DL et al. Prevention of chemical carcinogenesis by vitamin A and its synthetic analogues [retinoids]. Fed. Proc. 35, 1332–1338 (1976).
   PubMedGoogle Scholar
• Steinbach G, Lynch PM, Phillips RK et al. The effects of celecoxib, a cyclo-oxygenase inhibitor, in familial adenomatous polyposis. N. Engl. J Med. 342, 1946–1952 (2000).
   PubMed Web of Science ®Google Scholar
• Hong WK, Endicott J, Itri LM et al. 13-cis-retinoic acid in the treatment of oral leukoplakia. N. Engl. J. Med. 315, 1501–1505 (1986).
   PubMed Web of Science ®Google Scholar
• Hong WK, Lippman SM, Itri LM et al. Prevention of second primary tumors with isotretinoin in squamous cell carcinoma of the head and neck. N. Engl. J. Med. 323, 795–801 (1990).
   PubMed Web of Science ®Google Scholar
• Gudas LJ, Sporn MB, Roberts AB. Cellular biology and biochemistry of the retinoids. In: The retinoids. Sporn MB, Roberts AB, Goodman DS (Eds), Raven Press, NY, USA, 443–520 (1994).
   Google Scholar
• Deluca LM. Retinoids and their receptors in differentiation, embryogenesis and neoplasia. FASEB J. 5, 2923–2933 (1991).
   Google Scholar
• Lotan R. Retinoids and apoptosis: implication for cancer chemoprevention and therapy. J. Natl Cancer Inst. 87, 1655–1657 (1995).
   PubMed Web of Science ®Google Scholar
• Nagy L, Thomazy VA, Heyman RA et al. Retinoid-induced apoptosis in normal and neopastic tissues. Cell Death Diff. 5, 11–19 (1998).
   PubMed Web of Science ®Google Scholar
• Wolbach SB, Howe PR. Tissue changes following deprivation of fat-soluble vitamin A. J. Exp. Med. 42, 597–630 (1925).
   Google Scholar
• Kitareewan S, Pitha-Rowe I, Ma Y et al. The retinoids and cancer prevention mechanisms. In: Cancer Chemoprevention Volume I: Promising Cancer Chemopreventive Agents. Kelloff GJ, Hawk ET, Sigman CC (Eds). (2005) (In Press).
   Google Scholar
• Muto Y, Moriwaki H, Ninomiya M et al. Prevention of second primary tumors by an acyclic retinoid, polyprenoic acid, in patients with hepatocellular carcinoma. N. Engl. J. Med. 334, 1561–1567 (1996).
   PubMed Web of Science ®Google Scholar
• Mavne ST, Lippman SM. Retinoids, carotenoids and micronutrients. In: Cancer: Principles and Practice of Oncology. Sixth Edition. Devita VT, Hellman S, Rosenberg SA (Eds). Lippincott-Raven, PA, USA, 575–590 (1997).
   Google Scholar
• Krinsky NI. Actions of carotenoids in biologic systems. Ann. Rev. Nutr. 13, 561 (1993).
   PubMed Web of Science ®Google Scholar
• Peto R, Doll R, Buckley JD et al. Can dietary β-carotene materially reduce human cancer rates? Nature 290, 201–209 (1981).
   PubMed Web of Science ®Google Scholar
• Floyd RA. Role of free radicals in carcinogenesis and brain ischaemia. FASEB J. 4, 2587 (1990).
   PubMed Web of Science ®Google Scholar
• Chew BP, Wong TS, Shultz TD et al. Effects of conjugated dienoic derivatives of linoleic acid and β-carotene in modulating lymphocyte and macrophage function. Anticancer Res. 17, 1099–1106 (1997).
   PubMed Web of Science ®Google Scholar
• Murata T, Tamai H, Morinobu T et al. Effect of long-term administration of β-carotene on lymphocyte subsets in humans. Am. J. Clin. Nutr. 60, 597–602 (1994).
   PubMed Web of Science ®Google Scholar
• Toba T, Shidoji Y, Fujii J et al. Growth suppression and induction of heat-shock protein-70 by 9-cis β-carotene in cervical dysplasia-derived cells. Life Sci. 61, 839–845 (1997).
   PubMed Web of Science ®Google Scholar
• Muto Y, Fujii J, Shidoji Y et al. Growth retardation in human cervical dysplasia-derived cell lines by β-carotene through downregulation of epidermal growth factor receptor. Amer. J. Clin. Nutr. 62(6 Suppl.), S1535–S1540 (1995).
   PubMed Web of Science ®Google Scholar
• Nishino H, Murakoshi M, Ii T et al. Carotenoids in cancer chemoprevention. Cancer Metast. Rev. 21, 257–264 (2002).
   PubMed Web of Science ®Google Scholar
• Sies H, Stahl W. Lycopene: anti-oxidant and biological effects and its bioavailability in the human. Proc. Soc. Exp. Biol. Med. 218, 121–124 (1998).
   PubMed Web of Science ®Google Scholar
• Amir H, Karas M, Giat J et al. Lycopene and 1,25-dihydroxyvitamin D3 co-operate in the inhibition of cell cycle progression and induction of differentiation in HL-60 leukemic cells. Nutr. Cancer 33, 105–112 (1999).
   PubMed Web of Science ®Google Scholar
• Karas M, Amir H, Fishman D et al. Lycopene interferes with cell cycle progression and insulin-like growth Factor I signaling in mammary cancer cells. Nutr. Cancer 36, 101–111 (2000).
   PubMed Web of Science ®Google Scholar
• Stahl W, von Laar J, Martin HD et al. Stimuation of gap junctional communication: comparison of acyclo-retinoic acid and lycopene. Arch. Biochem. Biophys. 373, 271–274 (2000).
   PubMed Web of Science ®Google Scholar
• Heber D. Colorful cancer prevention: α-carotene, lycopene and lung cancer. Am. J. Clin. Nutr. 72, 901–902 (2000).
   PubMed Web of Science ®Google Scholar
• Mangelsdorf DJ, Umesono K, Evans RM. The retinoid receptors. In: The Retinoids: Biology, Chemistry and Medicine. Second Edition. Sporn MB, Roberts AB, Goodman DS (Eds). Raven Press, NY, USA, 319–349 (1994).
   Google Scholar
• Mangelsdorf DJ, Thummel C, Beato M et al. The nuclear receptor superfamily: The second decade. Cell 83, 835–839 (1995).
   PubMed Web of Science ®Google Scholar
• Chambon P. A decade of molecular biology of retinoic acid receptors. FASEB J. 10, 940–954 (1996).
   PubMed Web of Science ®Google Scholar
• Zelent A, Mendelson C, Kastner P et al. Differentially expressed isoforms of the mouse retinoic acid receptor β are generated by usage of two promoters and alternative splicing. EMBO J. 10, 71–81 (1991).
   PubMed Web of Science ®Google Scholar
• Napgal S, Zelent A, Chambon P. RAR-β-4, a retinoic acid receptor isoform is generated from RAR-β-2 by alternative splicing and usage of a CUG initiator codon. Proc. Natl Acad. Sci. USA 89, 2718–2722 (1992).
   PubMed Web of Science ®Google Scholar
• Hu X, Lazar MA. Transcriptional repression by nuclear receptors. Trends Endocrinol. Metab. 11, 6–10 (2000).
   PubMed Web of Science ®Google Scholar
• Germain P, Iyer J, Zechel C et al. Co-regulator recruitment and the mechanism of retinoic acid synergy. Nature 415, 187–192 (2002).
   PubMed Web of Science ®Google Scholar
• Rachez C, Freedman LP. Mediator complexes and transcription. Curr. Opin. Cell Biol. 13, 274–280 (2001).
   PubMed Web of Science ®Google Scholar
• Altucci L, Gronemeyer H. The promise of retinoids to fight against cancer. Nature Rev. Cancer 1, 181–193 (2001).
   PubMed Web of Science ®Google Scholar
• Renaud JP, Rochel N, Ruff M et al. Crystal structure of the RAR-γ ligand-binding domain bound to all-trans-retinoic acid. Nature 378, 681–689 (1995).
   PubMed Web of Science ®Google Scholar
• Davies P, Lippman SM. Biologic basis of retinoid pharmacology: implications for cancer prevention and therapy. Adv. Oncol. 12, 2–10 (1996).
   Google Scholar
• Lala DS, Mukherjee R, Schulman IG et al. Activation of specific RXR heterodimers by an antagonist of RXR homodimers. Nature 383, 450–453 (1996).
   PubMed Web of Science ®Google Scholar
• Mukherjee R, Davies PJ, Crombie DL et al. Sensitization of diabetic and obese mice to insulin by retinoid X receptor agonists. Nature 386, 407–410 (1997).
   PubMed Web of Science ®Google Scholar
• Perlman T, Evans RM. Nuclear receptors in Sicily: all in the family. Cell 90, 391–397 (1997).
   PubMed Web of Science ®Google Scholar
• Bischoff ED, Gottardis MM, Moon TE et al. Beyond tamoxifen: the retinoid X receptor-selective ligand LGD1069 (Targretin) causes complete regression of mammary carcinoma. Cancer Res. 58, 479–484 (1998).
   PubMed Web of Science ®Google Scholar
• Gottardis MM, Bischoff ED, Shirley MA et al. Chemoprevention of mammary carcinoma by LGD1069 (Targretin): an RXR-selective ligand. Cancer Res. 56, 5566–5570 (1996).
   PubMed Web of Science ®Google Scholar
• Mariani L, Formelli F, De Palo G et al. Chemoprevention of breast cancer with fenretinide (4-HPR): study of long-term visual and opththalmologic tolerability. Tumori 82, 444–449 (1996).
   PubMed Web of Science ®Google Scholar
• Costa A, Formelli F, Chiesa F et al. Prospects of chemoprevention of human cancers with the synthetic retinoid fenretinide. Cancer Res. 54, 2032S–2037S (1994).
   PubMed Web of Science ®Google Scholar
• Dimery IW, Hong WK, Lee JJ et al. Phase I trial of α-tocopherol effects on 13-cis-retinoic acid toxicity. Ann Onc. 8, 85–89 (1997).
   PubMed Web of Science ®Google Scholar
• Besa EC, Abrahm JL, Bartholomew MJ et al. Treatment with 13-cis-retinoic acid in transfusion-dependent patients with myelodysplastic syndrome and decreased toxicity with addition of α-tocopherol. Am. J. Med. 89, 739–747 (1990).
   PubMed Web of Science ®Google Scholar
• Langston AW, Thompson JR, Gudas LJ. Retinoic acid-responsive enhancers located 3´ of the Hox A and Hox B homeobox gene clusters. Functional analysis. J. Biol. Chem. 272, 2167–2175 (1997).
   PubMed Web of Science ®Google Scholar
• Clifford JL, Menter DG, Wang M et al. Retinoid receptor-dependent and -independent effects of N-(4-hydroxyphenyl) retinamide in F9 embryonal carcinoma cells. Cancer Res. 59, 14–18 (1999).
   PubMed Web of Science ®Google Scholar
• Oridate N, Suzuki S, Higuchi M et al. Involvement of reactive oxygen species in N-(4-hydroxyphenyl) retinamide-induced apoptosis in cervical carcinoma cells. J. Natl Cancer Inst. 89, 1191–1198 (1997).
   PubMed Web of Science ®Google Scholar
• Mulshine JL, De Luca LM, Dedrick RL. Regional delivery of retinoids: a new approach to early lung cancer intervention. Clin. Biol. Basis Lung Cancer Prev. 24, 273–283 (1998).
   Google Scholar
• Cao Y, Pearman AT, Zimmerman GA et al. Intracellular unesterified arachidonic acid signals apoptosis. Proc. Natl Acad. Sci. USA 97, 11280–11285 (2000).
   PubMed Web of Science ®Google Scholar
• Chan TA, Morin PJ, Vogelstein B et al. Mechanisms underlying nonsteroidal anti-inflammatory drug-mediated apoptosis. Proc. Natl Acad. Sci. USA 95, 681–686 (1998).
   PubMed Web of Science ®Google Scholar
• Tsuji M, DuBois RN. Alterations in cellular adhesion and apoptosis in epithelial cells overexpressing prostaglandin endoperoxide synthase 2. Cell 83, 493–501 (1995).
   PubMed Web of Science ®Google Scholar
• Majima M, Isono M, Ikeda Y et al. Significant roles of inducible cyclooxgenase (COX-2) in angiogenesis in rat. Jpn J. Pharmacol. 75, 105–114 (1997).
   PubMedGoogle Scholar
• Sharma S, Stolina M, Yang SC et al. Tumor cyclooxygenase-2-dependent suppression of dendritic cell function. Clin. Cancer Res. 9, 961–968 (2003).
   PubMed Web of Science ®Google Scholar
• Cao Y, Prescott SM. Many actions of cyclooxygenase-2 in cellular dynamics and in cancer. J. Cell Physiol. 190, 279–286 (2002).
   PubMed Web of Science ®Google Scholar
• Castonguay A, Rioux N, Duperron C et al. Inhibition of lung tumorigenesis by NSAIDS: a working hypothesis. Exp. Lung Res. 24, 605–615 (1998).
   PubMed Web of Science ®Google Scholar
• Wolff H, Saukkonen K, Anttila S et al. Expression of cyclooxygenase-2 in human lung carcinoma. Cancer Res. 58, 4997–5001 (1998).
   PubMed Web of Science ®Google Scholar
• Hida T, Yatabe Y, Achiwa H et al. Increased expression of cyclooxgenase 2 occurs frequently in human lung cancers, specifically adenocarcinomas. Cancer Res. 58, 3761–3764 (1998).
   PubMed Web of Science ®Google Scholar
• Hosomi Y, Yokose T, Hirose Y et al. Increased cyclooxygenase-2 (COX-2) expression occurs frequently in precursor lesions of human adenocarcinomas of the lung. Lung Cancer 30, 73–81 (2000).
   PubMed Web of Science ®Google Scholar
• Khuri FR, Wu H, Lee JJ et al. Cyclooxygenase-2 overexpression is a marker of poor prognosis in Stage I non-small cell lung cancer. Clin. Cancer Res. 7, 861–867 (2001).
   PubMed Web of Science ®Google Scholar
• Harris RE, Beebe-Donk J, Schuller HM. Chemoprevention of lung cancer by non-steroidal anti-inflammatory drugs among cigarette smokers. Oncol. Rep. 9, 693–695 (2002).
   PubMed Web of Science ®Google Scholar
• Akhmedkhanov A, Toniolo P, Zeleniuch-Jacquotte A et al. Aspirin and lung cancer in women. Br. J. Cancer 87, 49–53 (2002).
   PubMed Web of Science ®Google Scholar
• Sebti SM, Hamilton AD. Farnesyltransferase and geranylgeranyltransferase I inhibitors and cancer therapy: lessons from mechanism and bench-to-bedside translational studies. Oncogene 19, 6584–6593 (2000).
   PubMed Web of Science ®Google Scholar
• Hill BT, Perrin D, Kruczynski A. Inhibiton of Ras-targeted prenylation: protein farnesyl transferase inhibitors revisited. Crit. Rev. Oncol. Hematol. 33, 7–23 (2000).
   PubMed Web of Science ®Google Scholar
• Zujewski J, Horak ID, Bol CJ et al. Phase I and pharmacokinetic study of farnesyl protein transferase inhibitor R115777 in advanced cancer. J. Clin. Oncol. 18, 927–941 (2000).
   PubMed Web of Science ®Google Scholar
• Westra WH, Baas IO, Hruban RH et al. K-Ras oncogene activation in atypical alveolar hyperplasias of the human lung. Cancer Res. 56, 2224–2228 (1996).
   PubMed Web of Science ®Google Scholar
• Lantry LE, Zhang Z, Yao R et al. Effect of farnesyltransferase inhibitor FTI-276 on established lung adenomas from A/J mice induced by 4-(methylnitrosamino)-1-(3-pyridyl)-1-butanone. Carcinogenesis 21, 113–116 (2000).
   PubMed Web of Science ®Google Scholar
• Salomon DS, Brandt R, Ciardiello F et al. Epidermal growth factor-related peptides and their receptors in human malignancies. Crit. Rev. Oncol. Hematol. 19, 183–232 (1995).
   PubMed Web of Science ®Google Scholar
• Richardson CM, Sharma RA, Cox KJ et al. Epidermal growth factor receptors and cyclooxygenase-2 in the pathogenesis of non-small cell lung cancer: potential targets for chemoprevention and systemic therapy. Lung Cancer 39, 1–13 (2003).
   PubMed Web of Science ®Google Scholar
• Fontanini G, Vignati S, Bigini D et al. Epidermal growth factor receptor (EGFR) expression in non-small cell lung cancer carcinomas correlates with metastatic involvement of hilar and mediastinal lymph nodes in the squamous subtype. Eur. J. Cancer 31, 178–183 (1995).
   Google Scholar
• Mukaida H, Toi M, Hirai T et al. Clinical significance of the expression of epidermal growth factor and its receptor in esophageal cancer. Cancer 68, 142–148 (1991).
   PubMed Web of Science ®Google Scholar
• Neal DE, Mellon K. Epidermal growth factor receptor and bladder cancer: a review. Urol. Int. 48, 365–371 (1992).
   PubMed Web of Science ®Google Scholar
• Sainsbury JR, Farndon JR, Needham GK et al. Epidermal-growth factor receptor status as predictor of early recurrence of and death from breast cancer. Lancet 1, 1398–1402 (1987).
   PubMed Web of Science ®Google Scholar
• Kurie JM, Shin HJC, Lee JS et al. Increased epidermal growth factor receptor expression in metaplastic bronchial epithelium. Clin. Cancer Res. 2, 1787–1793 (1996).
   PubMed Web of Science ®Google Scholar
• Rusch V, Klimstra D, Linkov I et al. Aberrant expression of p53 or the epidermal growth factor receptor is frequent in early bronchial neoplasia, and coexpression precedes squamous cell carcinoma development. Cancer Res. 55, 1365–1372 (1995).
   PubMed Web of Science ®Google Scholar
• Lonardo F, Dragnev KH, Freemantle SJ et al. Evidence for the epidermal growth factor receptor as a target for lung cancer prevention. Clin. Cancer Res. 8, 54–60 (2002).
   PubMed Web of Science ®Google Scholar
• Kris MG, Natale RB, Herbst RS et al. Efficacy of gefitinib, an inhibitor of the epidermal growth factor receptor tyrosine kinase, in symptomatic patients with non-small cell lung cancer: a randomized trial. JAMA 290, 2149–2158 (2003).
   PubMed Web of Science ®Google Scholar
• Forsythe B, Faulkner K. Overview of the tolerability of gefitinib (Iressa) monotherapy: clinical experience in non-small cell lung cancer. Drug Saf. 27, 1081–1092 (2004).
   PubMed Web of Science ®Google Scholar
• Lynch TJ, Bell DW, Sordella R et al. Activating mutations in the epidermal growth factor receptor underlying responsiveness of non-small cell lung cancer to gefitinib. N. Engl. J. Med. 350, 2129–2139 (2004).
   PubMed Web of Science ®Google Scholar
• Paez JG, Janne PA, Lee JC et al. EGFR mutations in lung cancer: correlation with clinical response to gefitinib therapy. Science 304, 1497–1500 (2004).
   PubMed Web of Science ®Google Scholar
• Pao W, Miller V, Zakowski M et al. EGF receptor gene mutations are common in lung cancer from ‘never smokers’ and are associated with sensitivity of tumors to gefitinib and erlotinib. Proc. Natl Acad. Sci. USA 101, 13306–13311 (2004).
   PubMed Web of Science ®Google Scholar
• Evans RM. The steroid and thyroid hormone receptor superfamily. Science 240, 889–895 (1988).
   PubMed Web of Science ®Google Scholar
• Schoonjans K, Martin G, Staels B et al. Peroxisome proliferator-activated receptors, orphans with ligands and functions. Curr. Opin. Lipidol. 8, 159–166 (1997).
   PubMed Web of Science ®Google Scholar
• Schoonjans K, Staels B, Auwerx J. The peroxisome proliferator activated receptors (PPARs) and their effects on lipid metabolism and adipocyte differentiation. Biochim. Biophys. Acta 1302, 93–109 (1996).
   PubMed Web of Science ®Google Scholar
• Berger J, Moller DE. The mechanisms of action of PPARs. Ann. Rev. Med. 53, 409–435 (2002).
   PubMed Web of Science ®Google Scholar
• Auwerx J. PPARγ, the ultimate thrifty gene. Diabetologica 42, 1033–1049 (1999).
   PubMed Web of Science ®Google Scholar
• Theocharis S, Kanelli H, Politi A et al. Expression of peroxisome proliferator activated receptor-γ in non-small cell lung carcinoma: correlation with histologic type and grade. Lung Cancer 36, 249–255 (2002).
   PubMed Web of Science ®Google Scholar
• Segawa Y, Yoshimura T, Hase T et al. Expression of peroxisome proliferator-activated receptor (PPAR) in human prostate cancer. Prostate 51, 108–116 (2002).
   PubMed Web of Science ®Google Scholar
• Mueller E, Sarraf P, Tontonoz P et al. Terminal differentiation of human breast cancer through PPRAγ. Mol. Cell 1, 465–470 (1998).
   PubMed Web of Science ®Google Scholar
• Keshamouni VG, Reddy RC, Arenberg DA et al. Peroxisome proliferator-activated receptor-γ activation inhibits tumor progression in non-small-cell lung cancer. Oncogene 23, 100–108 (2004).
   PubMed Web of Science ®Google Scholar
• Shen Q, Brown PH. Novel agents for the prevention of breast cancer: targeting transcription factors and signal transduction pathways. J. Mammary Gland Biol. Neoplasia 8, 45–73 (2003).
   PubMed Web of Science ®Google Scholar
• Lonardo F, Rusch V, Langenfield J et al. Overexpression of cyclins D1 and E is frequent in bronchial neoplasia and precedes squamous cell carcinoma development. Cancer Res. 59, 2470–2476 (1999).
   PubMed Web of Science ®Google Scholar
• Boyle JO, Langenfeld J, Lonardo F et al. Cyclin D1 proteolysis: a retinoid chemoprevention signal in normal, immortalized and transformed human bronchial epithelial cells. J. Natl Cancer Inst. 91, 373–379 (1999).
   PubMedGoogle Scholar
• Witschi H, Espiritu I, Suffia M et al. Expression of cyclin D1/2 in the lungs of strain A/J mice fed chemopreventive agents. Carcinogenesis 23, 289–294 (2002).
   PubMed Web of Science ®Google Scholar
• Papadimitrakopoulou VA, Izzo J, Mao L et al. Cyclin D1 and p16 alterations in advanced premalignant lesions of the upper aerodigestive tract: role in response to chemoprevention and cancer development. Clin. Cancer Res. 7, 3127–3134 (2001).
   PubMed Web of Science ®Google Scholar
• Engler TA, Furness K, Malhotra S et al. Novel, potent and selective cyclin D1/Cdk4 inhibitors: indolo[6,7-a]pyrrolo[3,4-c]carbazoles. Bioorg. Med. Chem. Lett. 13, 2261–2267 (2003).
   PubMed Web of Science ®Google Scholar
• Zochbauer-Muller S, Minna JD, Gazdar AF. Aberrant DNA methylation in lung cancer: biological and clinical implications. Oncologist 7, 451–457 (2002).
   PubMed Web of Science ®Google Scholar
• Virmani AK, Rathi A, Zochbauer-Muller S et al. Promoter methylation and silencing of the retinoic acid receptor-β gene in lung carcinomas. J. Natl Cancer Inst. 92, 1303–1307 (2000).
   PubMedGoogle Scholar
• Burbee DG, Forgacs E, Zochbauer-Muller S et al. Epigenetic inactivation of RASSF1A in lung and breast cancers and malignant phenotype suppression. J. Natl Cancer Inst. 93, 691–699 (2001).
   PubMed Web of Science ®Google Scholar
• Zochbauer-Muller S, Fong KM, Maitra A et al. 5´ CpG island methylation of the FHIT gene is correlated with loss of gene expression in lung and breast cancer. Cancer Res. 61, 3581–3585 (2001).
   PubMed Web of Science ®Google Scholar
• Toyooka KO, Toyooka S, Virmani AK et al. Loss of expression and aberrant methylation of the CDH13 (H-cadherin) gene in breast and lung carcinomas. Cancer Res. 61, 4556–4560 (2001).
   PubMed Web of Science ®Google Scholar
• Kellof GJ, Boon CW, Crowell JA et al. Risk biomarkers and current strategies for cancer prevention. J. Cell Biochem. Suppl. 25, 1–14 (1996).
   Google Scholar
• Lippman SM, Benner SE, Hong WK. Cancer chemoprevention. J. Clin. Oncol. 12, 851–873 (1994).
   PubMed Web of Science ®Google Scholar
• Workshop report. Biomarkers in cancer chemoprevention. In: Biomarkers in Cancer Chemoprevention, No.154. Miller AB, Bartsch H, Boffeta P, Dragsted L, Vainio H (Eds). IARC Scientific Publications, Lyon, France, 1–12 (2001).
   Google Scholar
• Lippman SM, Lee JS, Lotan R et al. Biomarkers as intermediate end points in chemoprevention trials. J. Natl Cancer Inst. 82, 555–560 (1990).
   PubMed Web of Science ®Google Scholar
• Srivastava S, Rossi SC. Early detection research program at the NCI. Int. J. Cancer 69, 35–37 (1996).
   PubMed Web of Science ®Google Scholar
• Sullivan Pepe M, Etzioni R, Feng Z et al. Phases of biomarker development for early detection of cancer. J. Natl Cancer Inst. 93, 1054–1061 (2001).
   PubMed Web of Science ®Google Scholar
• Prentice RL. Surrogate end points in clinical trials: definition and operational criteria. Stat. Med. 8, 431–440 (1989).
   PubMed Web of Science ®Google Scholar
• Buyse M, Molenberghs G. Criteria for the validation of surrogate end points in randomized experiments. Biometrics 54, 1014–1029 (1998).
   PubMed Web of Science ®Google Scholar
• a-tocopherol, β-Carotene Cancer Prevention Study Group. The effect of vitamin E and β-carotene on the incidence of lung cancer and other cancers in male smokers. N. Engl. J. Med. 330, 1029–1035 (1994).
   Google Scholar
• Omenn GS, Goodman GE, Thornquist MD et al. Effects of a combination of β-carotene and vitamin A on lung cancer and cardiovascular disease. N. Engl. J. Med. 334, 1150–1155 (1996).
   PubMed Web of Science ®Google Scholar
• Block G, Patterson B, Subar A. Fruit, vegetables and cancer prevention: a review of the epidemiological evidence. Nutr. Cancer 18, 1–29 (1992).
   PubMed Web of Science ®Google Scholar
• van Poppel G, Goldbohm RA. Epidemiologic evidence for β-carotene and cancer prevention. Am. J. Clin. Nutr. 62, S1393–S1402 (1995).
   PubMed Web of Science ®Google Scholar
• Menkes MS, Comstock GW, Vuilleumier JP et al. Serum β-carotene, vitamins A and E, selenium and the risk of lung cancer. N. Engl. J. Med. 315, 1250–1254 (1986).
   PubMed Web of Science ®Google Scholar
• Stryker WS, Kaplan LA, Stein EA et al. The relation of diet, cigarette smoking, and alcohol consumption to plasma β-carotene and α-tocopherol levels. Am. J. Epidemiol. 127, 283–296 (1988).
   PubMed Web of Science ®Google Scholar
• Greenwald P. β-carotene and lung cancer: a lesson for future chemoprevention investigations? J. Natl Cancer Inst. 95, E1 (2003).
   Google Scholar
• Handelman GJ, Packer L, Cross CE. Destruction of tocopherols, carotenoids, and retinol in human plasma by cigarette smoke. Am. J. Clin. Nutr. 63, 559–565 (1996).
   PubMed Web of Science ®Google Scholar
• Stram DO, Wu AH. β-carotene and lung cancer: a lesson for future chemoprevention investigations? J. Natl Cancer Inst. 95, E4 (2003).
   PubMedGoogle Scholar
• Omaye ST, Krinsky NI, Kagan VE et al. β-carotene: friend or foe? Fundam. Appl. Toxicol. 40, 163–174 (1997).
   PubMedGoogle Scholar
• Buiatti E. An overview of recent results of chemoprevention trials. In: The Scientific Basis of Cancer Chemoprevention. Maltoni C, Soffritti M, Davis W (Eds), Elsevier, Amsterdam, The Netherlands, 257–266 (1996).
   Google Scholar
• Paolini M, Cantelli-Forti G, Perocco P et al. Co-carcinogenic effect of β-carotene. Nature 398, 760–761 (1999).
   PubMed Web of Science ®Google Scholar
• Perocco P, Paolini M, Mazzullo M et al. β-carotene as enhancer of cell transforming activity of powerful carcinogens and cigarette-smoke condensate on BALB/c 3T3 cells in vitro. Mutat Res. 440, 83–90 (1999).
   PubMed Web of Science ®Google Scholar
• Salgo MG, Cueto R, Winston GW et al. β-carotene and its oxidation products have different effects on microsome mediated binding of benzo[a]pyrene to DNA. Free Radical Biol. Med. 26, 162–173 (1999).
   PubMed Web of Science ®Google Scholar
• Hennekens CH, Buring JE, Manson JE et al. Lack of effect of long-term supplementation with β-carotene on the incidence of malignant neoplasms and cardiovascular disease. N. Engl. J. Med. 334, 1145–1149 (1996).
   PubMed Web of Science ®Google Scholar
• Lee JS, Lippman SM, Benner SE et al. Randomized placebo-controlled trial of isotretinoin in chemoprevention of bronchial squamous metaplasia. J. Clin. Oncol. 12, 937–945 (1994).
   PubMed Web of Science ®Google Scholar
• Kurie JM, Lee JS, Khuri FR et al. N-(4-hydroxyphenyl)retinamide in the chemoprevention of squamous metaplasia and dysplasia of the bronchial epithelium. Clin. Cancer Res. 6, 2973–2979 (2000).
   PubMed Web of Science ®Google Scholar
• Arnold AM, Browman GP, Levine MN et al. The effect of the synthetic retinoid etredinate on sputum cytology: results from a randomized trial. Br. J. Cancer 65, 737–743 (1992).
   PubMed Web of Science ®Google Scholar
• McLarty JW, Holiday DB, Girard WM et al. β-carotene, vitamin A, and lung cancer chemoprevention: results of an intermediate end point study. Am. J. Clin. Nutr. 62, S1431–S1438 (1995).
   Web of Science ®Google Scholar
• Heimbuger DC, Alexander CB, Birch et al. Improvement in bronchial squamous metaplasia in smokers treated with folate and vitamin B12. Report of a preliminary randomized double-blind intervention trial. JAMA 259, 1525–1530 (1988).
   PubMed Web of Science ®Google Scholar
• Lippman SM, Benner SE, Hong WK. Cancer chemoprevention. J. Clin. Oncol. 12, 851–873 (1994).
   PubMed Web of Science ®Google Scholar
• Kurie JM, Lotan R, Lee JS et al. Treatment of former smokers with 9-cis-retinoic acid reverses loss of retinoic acid receptor-β expression in the bronchial epithelium: results from a randomized placebo-controlled trial. J. Natl Cancer Inst. 95, 206–214 (2003).
   PubMed Web of Science ®Google Scholar
• Khuri FR, Lotan R, Kemp B et al. Retinoic acid receptor-β as a prognostic indicator in Stage I non-small-cell lung cancer. J. Clin. Oncol. 18, 2798–2804 (2000).
   PubMed Web of Science ®Google Scholar
• Lam S, MacAulay C, Le Riche JC et al. A randomized Phase IIb trial of anethole dithiolethione in smokers with bronchial dysplasia. J. Natl Cancer Inst. 94, 1001–1009 (2002).
   PubMed Web of Science ®Google Scholar
• Benner SE, Pajak TF, Lippman SM et al. Prevention of second primary tumors with isotretinoin in patients with squamous cell carcinoma of the head and neck: long-term follow-up. J. Natl Cancer Inst. 86, 140–141 (1994).
   PubMedGoogle Scholar
• Pastorino U, Infante M, Maioli M et al. Adjuvant treatment of Stage I lung cancer with high-dose vitamin A. J. Clin. Oncol. 11, 1216–1222 (1993).
   PubMed Web of Science ®Google Scholar
• van Zandwijk N, Dalesio O, Pastorino U et al. EUROSCAN, a randomized trial of vitamin A and N-acetylcysteine in patients with head and neck cancer or lung cancer. For the European Organization for Research and Treatment of Cancer Head and Neck and Lung Cancer Co-operative Groups. J. Natl Cancer Inst. 92, 977–986 (2000).
   PubMed Web of Science ®Google Scholar
• Lippman SM, Lee JJ, Karp DD et al. Randomized Phase III intergroup trial of isotretinoin to prevent second primary tumors in Stage I non-small-cell lung cancer. J. Natl Cancer Inst. 93, 605–618 (2001).
   PubMed Web of Science ®Google Scholar
• Virmani AK, Rathi A, Zochbauer-Muller S et al. Promoter methylation and silencing of the retinoic acid receptor-β gene in lung carcinomas. J. Natl Cancer Inst. 92, 1303–1307 (2000).
   PubMedGoogle Scholar
• Ravi RK, Scott FM, Cuttitta F et al. Induction of gastrin-releasing peptide by all-trans retinoic acid in small-cell lung cancer cells. Oncol. Rep. 5, 497–501 (1998).
   PubMed Web of Science ®Google Scholar
• Siegfried JM, DeMichele MA, Hunt JD et al. Expression of mRNA for gastrin-releasing peptide receptor by human bronchial epithelial cells: association with prolonged tobacco exposure and responsiveness to Bombesin-like peptides. Am. J. Respir. Crit. Care Med. 156, 358–366 (1997).
   PubMed Web of Science ®Google Scholar
• Manna SK, Aggarwal BB. All-trans-retinoic acid upregulates TNF receptors and potentiates TNF-induced activation of nuclear factors-κB, activated protein-1 and apoptosis in human lung cancer cells. Oncogene. 19, 2110–2119 (2000).
   PubMed Web of Science ®Google Scholar
• Pei XH, Nakanishi Y, Takayama K et al. Benzo[a]pyrene activates the human p53 gene through induction of nuclear factor κB activity. J. Biol. Chem. 274, 35240–35246 (1999).
   PubMed Web of Science ®Google Scholar
• Mayne ST, Cartmel B, Baum M et al. Randomized trial of supplemental β-carotene to prevent second head and neck cancer. Cancer Res. 61, 1457–1463 (2001).
   PubMed Web of Science ®Google Scholar
• Khuri FR, Lee JJ, Lippman SM et al. Isotretinoin effects on head and neck cancer recurrence and second primary tumors. Proc. Am. Soc. Clin. Oncol. 22, 90 (2003).
   Google Scholar
• Clark LC, Combs GF Jr, Turnbull BW et al. Effects of selenium supplementation for cancer prevention in patients with carcinoma of the skin. JAMA 276, 1957–1963 (1996).
   PubMed Web of Science ®Google Scholar
• Blot WJ, Li JY, Taylor RR et al. Linxian nutrition intervention trials: supplementation with specific vitamin/mineral combinations, cancer incidence, and disease-specific mortality in the general population. J. Natl Cancer Inst. 85, 1483–1492 (1993).
   PubMed Web of Science ®Google Scholar